—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Integrating plasma next-generation sequencing (NGS) alongside tissue testing when determining lung cancer diagnosis may improve outcomes for patients. Carrying out plasma next-generation sequencing ...

Please provide your email address to receive an email when new articles are posted on . National Comprehensive Cancer Network guidelines recommend all patients with advanced nonsquamous non-small cell ...

The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Charu Aggarwal, M.D., MPH: Recent data show that there are many challenges. We saw presentations at this year’s American Society of Clinical Oncology annual meeting where rates of molecular testing ...

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...

Charu Aggarwal, M.D., MPH: I normally approach molecular testing exactly how you pointed out, Hoss. I spend at least more than half of my first visit with my patients with newly diagnosed lung cancer ...

"Clinicians performing tumor biopsy need to ensure that there’s adequate tissue for both diagnosis and NGS testing. Having immediate pathology review of biopsy specimens in the operating room can ...

William Beaumont Army Medical Center's Department of Pathology recently conducted a study to monitor compliance rate and to gauge turnaround times of biomarker testing for non-small cell lung cancers ...

REDWOOD CITY, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), announced that the positive results from the NILE study, a head-to-head comparison of the Guardant360® ...